SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bafna Pharmaceuticals widens net loss to Rs 2.08 crore in Q4

01 Jun 2012 Evaluate

Bafna Pharmaceuticals has reported a widening of its standalone net loss to Rs 2.08 crore for the quarter ended March 31, 2012 as compared to a net loss of Rs 0.85 crore over the same period previous fiscal. However, the net sales of the company increased by 10.57% to Rs 32.73 crore in the quarter under review from Rs 29.60 crore in same period year ago.

For the full year, the company’s net profit declined by 38.05% at Rs 20.74 crore against Rs 33.48 crore for the previous fiscal however, net sales of the company rose 19.43% to Rs 120.98 crore for FY12 from Rs 101.30 crore for FY11.

Bafna Pharma Share Price

138.00 -7.00 (-4.83%)
13-Apr-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.00
Cipla 1212.95
Zydus Lifesciences 920.00
Lupin 2316.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×